Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial

被引：0
|
作者：
Tetsu Hayashida
Hiromitsu Jinno
Katsuaki Mori
Hiroki Sato
Akira Matsui
Takashi Sakurai
Hiroaki Hattori
Shin Takayama
Masahiro Wada
Maiko Takahashi
Hirohito Seki
Tomoko Seki
Aiko Nagayama
Akiko Matsumoto
Yuko Kitagawa
机构：
[1] Keio University School of Medicine,Department of Surgery
[2] Teikyo University School of Medicine,Department of Surgery
[3] Hino Municipal Hospital,Department of Surgery
[4] Mito Red Cross Hospital,Department of Surgery
[5] National Hospital Organization Tokyo Medical Center,Department of Surgery
[6] JCHO Saitama Medical Center,Division of Surgery
[7] Federation of National Public Service Personnel Mutual Aid Associations,Department of Surgery
[8] Tachikawa Hospital,Department of surgery
[9] Tokyo Dental College Ichikawa General Hospital,Department of Surgery
[10] Sanokousei general hospital,undefined
来源：
BMC Cancer | / 18卷
关键词：
Breast cancer; Eribulin; Phase II trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial
    Cortes, Javier
    Hudgens, Stacie
    Twelves, Chris
    Perez, Edith A.
    Awada, Ahmad
    Yelle, Louise
    McCutcheon, Susan
    Kaufman, Peter A.
    Forsythe, Anna
    Velikova, Galina
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 154 (03) : 509 - 520
  • [22] A phase II trial of paclitaxel (Taxol(R)) as first line treatment in advanced breast cancer
    Swain, SM
    Honig, SF
    Tefft, MC
    Walton, L
    INVESTIGATIONAL NEW DRUGS, 1995, 13 (03) : 217 - 222
  • [23] Goserelin plus letrozole as first- or second-line hormonal treatment in premenopausal patients with advanced breast cancer
    Yao, Shuyang
    Xu, Binghe
    Li, Qing
    Zhang, Pin
    Yuan, Peng
    Wang, Jiayu
    Ma, Fei
    Fan, Ying
    ENDOCRINE JOURNAL, 2011, 58 (06) : 509 - 516
  • [24] Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer
    Sakaguchi, Koichi
    Nakatsukasa, Katsuhiko
    Koyama, Hiroshi
    Kato, Makoto
    Sakuyama, Akira
    Matsuda, Takayuki
    Tsunoda, Nobuyuki
    Fujiwara, Ikuya
    Yamaguchi, Masahide
    Tanaka, Hiroki
    Onishi, Kazuyoshi
    Onishi, Mie
    Yoshino, Yuji
    Kikuchi, Takashi
    Taguchi, Tetsuya
    ANTICANCER RESEARCH, 2018, 38 (07) : 4073 - 4081
  • [25] Pembrolizumab plus eribulin in hormone receptore-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase II trial
    Perez-Garcia, Jose M.
    Llombart-Cussac, Antonio
    Cortes, Maria G.
    Curigliano, Giuseppe
    Lopez-Miranda, Elena
    Alonso, Jose L.
    Bermejo, Begona
    Calvo, Lourdes
    Caranana, Vicente
    de la Cruz Sanchez, Susana
    Vazquez, Raul M.
    Prat, Aleix
    Borrego, Manuel R.
    Sampayo-Cordero, Miguel
    Segui-Palmer, Miguel A.
    Soberino, Jesus
    Malfettone, Andrea
    Schmid, Peter
    Cortes, Javier
    EUROPEAN JOURNAL OF CANCER, 2021, 148 : 382 - 394
  • [26] CapOX as neoadjuvant chemotherapy for locally advanced operable colon cancer patients: a prospective single-arm phase Ⅱ trial
    Fangqi Liu
    Li Yang
    Yuchen Wu
    Cong Li
    Jiang Zhao
    Adili Keranmu
    Hongtu Zheng
    Dan Huang
    Lei Wang
    Tong Tong
    Junyan Xu
    Ji Zhu
    Sanjun Cai
    Ye Xu
    ChineseJournalofCancerResearch, 2016, 28 (06) : 589 - 597
  • [27] Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study
    Sakura Iizumi
    Tatsunori Shimoi
    Natsuko Tsushita
    Seiko Bun
    Akihiko Shimomura
    Emi Noguchi
    Makoto Kodaira
    Mayu Yunokawa
    Kan Yonemori
    Chikako Shimizu
    Yasuhiro Fujiwara
    Kenji Tamura
    BMC Cancer, 17
  • [28] Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study
    Iizumi, Sakura
    Shimoi, Tatsunori
    Tsushita, Natsuko
    Bun, Seiko
    Shimomura, Akihiko
    Noguchi, Emi
    Kodaira, Makoto
    Yunokawa, Mayu
    Yonemori, Kan
    Shimizu, Chikako
    Fujiwara, Yasuhiro
    Tamura, Kenji
    BMC CANCER, 2017, 17
  • [29] Metronomic Chemotherapy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Phase II Trial
    Montagna, Emilia
    Bagnardi, Vincenzo
    Cancello, Giuseppe
    Sangalli, Claudia
    Pagan, Eleonora
    Iorfida, Monica
    Mazza, Manuelita
    Mazzarol, Giovanni
    Dellapasqua, Silvia
    Munzone, Elisabetta
    Goldhirsch, Aaron
    Colleoni, Marco
    BREAST CARE, 2018, 13 (03) : 177 - 181
  • [30] Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer
    Bianchi, Giulia
    Loibl, Sibylle
    Zamagni, Claudio
    Salvagni, Stefania
    Raab, Guenter
    Siena, Salvatore
    Laferriere, Nicole
    Pena, Carol
    Lathia, Chetan
    Bergamini, Loredana
    Gianni, Luca
    ANTI-CANCER DRUGS, 2009, 20 (07) : 616 - 624
12345